new glp 1 drug retatrutide Subcutaneous Fat Loss Results: What Clinical Trials Reveal About Effectiveness and Safety Retatrutide Weight Loss Results:Trial Data
Description
They evaluate the manufacturers knowledge of the risks associated with its medication, its communications with the FDA, and the adequacy of its warning labels
Conte, C., Hall, K
Virchows Archiv B Cell Pathology
Obesity is a chronic disease exacerbated by a complex array of biological, social, environmental, and structural forces
Reports of phase 2 data using 9 mg shows a placebo-adjusted mean weight loss of 15.4% after 24 weeks and 18.6% after 48 weeks (89)
[DOI] [PubMed] [Google Scholar] 714.Burmeister M.A., Ayala J., Drucker D.J., Ayala J.E
